- Cough, Mucus, and Respiratory Health: A Complete Guide - August 18, 2025
- Flogoprofen: what it's used for and how to take it - June 21, 2025
- What is Movicol oral solution in sachet used for and how to take it? - June 18, 2025
Data Cancer Genetics (DCG) has launched an innovative video reporting service that assesses the effectiveness of chemotherapy drugs in vitro. Using artificial intelligence (AI), this platform allows oncologists to observe in real time how a patient’s tumor cells respond to chemotherapy drugs. This revolutionary approach offers unprecedented personalization in cancer treatment, helping to select the most effective drugs.
Advanced technology and real-time analysis of cancer
DCG's new platform uses high-resolution videos to analyze the action of drugs on tumor cells. These slow-motion videos allow for automated and accurate quantification of cell killing rates. The analysis is performed in real time, facilitating rapid and well-informed treatment decisions.
Reducing uncertainty in treatment
With this service, the oncologists They can avoid empirical drug selection, a process that often results in ineffective treatments. The absence of molecular biomarkers for many drugs increases the risks of therapeutic failure. Visual analysis of DCG makes it possible to see, before starting treatment, how tumor cells respond to various drugs, thus reducing the use of ineffective therapies.
Personalized approach
Using this service not only improves the accuracy of cancer treatment, but also reduces side effects, minimizing exposure to unnecessary drugs. The reports provided to oncologists are also designed to be easy to understand for patients, ensuring transparency in clinical decisions. According to Dr. Darshana Patil, Senior Director of Global Strategy and Medical Affairs at DCG, this technology offers “clear and verifiable visual evidence” to guide treatment.
Efficiency
DCG’s platform has been validated in rigorous trials and adopted by leading cancer centers. Early results show increased success in treating cancer patients, resulting in higher patient satisfaction. Dr. Vineet Datta, Senior Director of Global Strategy and Business Development at DCG, highlights that this approach “revolutionizes cancer care by optimizing treatment selection and improving patient outcomes.”
This breakthrough opens new doors for patients with solid tumor cancer. DCG’s in vitro chemosensitivity test is now available to evaluate both standard and off-label drugs essential for treating resistant tumors. The transparency and accuracy of this test positions DCG as a leader in the field of personalized oncology, which promises to transform the cancer treatment landscape in the coming years.
The demo video of this platform is available at this link.
